Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists (NSAs), reported unaudited financial results for the third quarter ended Dec. 31, 2025. The company highlighted continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, along with a completed leadership transition and corporate rebranding.
Helus Pharma ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio and upcoming clinical data milestones in 2026.
The company's HLP003 program, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, is designed as an adjunctive treatment for major depressive disorder. HLP004 is being developed for generalized anxiety disorder. Both programs are based on proprietary NSAs that aim to activate serotonin pathways believed to promote neuroplasticity.
Helus Pharma, the commercial operating name of Cybin Inc., aims to address the large unmet need for people suffering from depression, anxiety and other mental health conditions. The company operates in Canada, the United States, the United Kingdom and Ireland.
For more details, the full press release is available at https://ibn.fm/VigPf. Updates and additional information can be found on the company's website at www.helus.com.
